---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-006057"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:43:14.283034+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aligos Q3 net loss $19.3M; MASH drug shows up to 46.2% liver fat reduction

## Summary
- Net loss of $19.3M ($3.07 per share) vs $18.0M ($10.37 per share) in Q3 2023.
- Cash & investments $74.9M, down from $135.7M at Dec 31, 2023; runway through end of 2025.
- MASH candidate ALG-055009 achieved placebo-adjusted median relative liver fat reduction up to 46.2% at Week 12; favorable tolerability.
- CHB candidate ALG-000184 progressing to Phase 2 next year; FDA and China NMPA agree on primary endpoint.
- COVID protease inhibitor ALG-097558 to begin externally funded clinical studies in 2024.

## SEC filing metadata
- accession: 0001171843-24-006057
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184324006057/0001171843-24-006057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184324006057/f8k_110624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-006057
- JSON: https://secwatch.observer/filing/0001171843-24-006057.json
- Plain text: https://secwatch.observer/filing/0001171843-24-006057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.